This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winner, P.
Right arrow Articles by Peykamian, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winner, P.
Right arrow Articles by Peykamian, M.
Related Collections
Right arrow Neurology & Psychiatry

PEDIATRICS Vol. 106 No. 5 November 2000, pp. 989-997

A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents

Received Aug 6, 1999; accepted Feb 1, 2000.

Paul Winner*, A. David RothnerDagger , Joel Saper§, Robert Nettparallel , Mahnaz Asgharnejad, Antonio Laurenza, Randall Austin, and Margaret Peykamian

From the * Palm Beach Headache Center, West Palm Beach, Florida; Dagger  Cleveland Clinic, Cleveland, Ohio; § Michigan Headache and Neurological Institute, Ann Arbor, Michigan; parallel  San Antonio Center for Clinical Research, San Antonio, Texas; and  Glaxo Wellcome Inc, Research Triangle Park, North Carolina.

Objective.  To compare the efficacy and tolerability of sumatriptan nasal spray (NS; 5 mg, 10 mg, and 20 mg) with placebo for the treatment of acute migraine in adolescents.

Methods.  A randomized, double-blind, placebo-controlled, single-attack study was conducted in 653 US adolescents (12-17 years of age). Patients with at least a 6-month history of migraine, who met International Headache Society criteria for migraine (with or without aura) were eligible for participation. Headache relief 2 hours postdose, complete relief, presence or absence of associated symptoms, headache recurrence, and use of rescue medications were recorded. The primary efficacy endpoint was headache relief 2 hours postdose sumatriptan NS (20 mg) versus placebo. Safety and tolerability were assessed by examining adverse events, changes in electrocardiograms, vital signs, physical examinations, and clinical laboratory tests.

Results.  Headache relief 1 hour postdose was significantly greater for patients using 10 mg (56%) and 20 mg (56%) of sumatriptan NS compared with placebo (41%). Headache relief 2 hours postdose was significantly greater for patients using 5 mg of sumatriptan NS (66%) compared with placebo (53%), and approached statistical significance for 20 mg (63%) compared with placebo (53%). Complete relief 2 hours postdose was significantly greater for patients using 20 mg of sumatriptan NS compared with placebo (36% vs 25%, respectively). Each dose of sumatriptan (5 mg, 10 mg, and 20 mg) was superior to placebo with respect to the cumulative percentages of patients first reporting headache relief within 2 hours of dosing (Kaplan-Meier). The sumatriptan 20-mg dose was superior to placebo with respect to the cumulative percentages of patients first reporting complete relief within 2 hours of dosing (Kaplan-Meier). Photophobia and phonophobia were significantly reduced 2 hours postdose for sumatriptan NS (20 mg), compared with placebo (36% vs 48% and 25% vs 44%, respectively). Taste disturbance was the most commonly reported adverse event (2%, 19%, 30%, and 26% for placebo, 5 mg, 10 mg, and 20 mg, respectively). No drug-related serious adverse events or clinically relevant changes in laboratory parameters, electrocardiograms, or vital signs were reported.

Conclusions.  Sumatriptan NS is effective and well-tolerated for the treatment of acute migraine in adolescents, with the 20-mg dose providing the best overall efficacy and tolerability profiles.  Key words:  migraine, sumatriptan, adolescents, pediatric.




This article has been cited by other articles:


Home page
 EDUCATION AND PRACTICEHome page
R W Newton
Childhood headache
Arch. Dis. Child. Ed. Pract., August 1, 2008; 93(4): 105 - 111.
[Full Text] [PDF]

Home page
 PediatricsHome page
D. W. Lewis, P. Winner, A. D. Hershey, W. W. Wasiewski, and on behalf of the Adolescent Migraine Steering Comm
Efficacy of Zolmitriptan Nasal Spray in Adolescent Migraine
Pediatrics, August 1, 2007; 120(2): 390 - 396.
[Abstract] [Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
S. Ryan
Medicines for migraine
Arch. Dis. Child. Ed. Pract., April 1, 2007; 92(2): ep50 - ep55.
[Full Text] [PDF]

Home page
 Pediatr. Rev.Home page
D. W. Lewis
Pediatric Migraine
Pediatr. Rev., February 1, 2007; 28(2): 43 - 53.
[Full Text] [PDF]

Home page
 JAMAHome page
D. K. Benjamin Jr, P. B. Smith, M. D. Murphy, R. Roberts, L. Mathis, D. Avant, R. M. Califf, and J. S. Li
Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
JAMA, September 13, 2006; 296(10): 1266 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Evers, A. Rahmann, C. Kraemer, G. Kurlemann, O. Debus, I. W. Husstedt, and A. Frese
Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen
Neurology, August 8, 2006; 67(3): 497 - 499.
[Abstract] [Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
N P Barnes and S Jayawant
MIGRAINE
Arch. Dis. Child. Ed. Pract., October 1, 2005; 90(3): ep53 - ep57.
[Full Text] [PDF]

Home page
 PediatricsHome page
L. Damen, J. K.J. Bruijn, A. P. Verhagen, M. Y. Berger, J. Passchier, and B. W Koes
Symptomatic Treatment of Migraine in Children: A Systematic Review of Medication Trials
Pediatrics, August 1, 2005; 116(2): e295 - e302.
[Abstract] [Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
A. D. Hershey and P. K. Winner
Pediatric Migraine: Recognition and Treatment
J Am Osteopath Assoc, April 1, 2005; 105(4_suppl): 2S - 8S.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Lewis, S. Ashwal, A. Hershey, D. Hirtz, M. Yonker, and S. Silberstein
Practice Parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society
Neurology, December 28, 2004; 63(12): 2215 - 2224.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Managing migraine in children
DTB, April 1, 2004; 42(4): 25 - 28.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. L. Christensen, R. K. Mottern, J. T. Jabbour, and E. Fuseau
Pharmacokinetics of Sumatriptan Nasal Spray in Children
J. Clin. Pharmacol., April 1, 2004; 44(4): 359 - 367.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Ahonen, M. L. Hamalainen, H. Rantala, and K. Hoppu
Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial
Neurology, March 23, 2004; 62(6): 883 - 887.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Landy
Migraine throughout the life cycle: Treatment through the ages
Neurology, March 9, 2004; 62(90052): S2 - 8.
[Abstract] [Full Text]

Home page
 J Child NeurolHome page
A. Pakalnis, D. Kring, and J. Paolicchi
Parental Satisfaction With Sumatriptan Nasal Spray in Childhood Migraine
J Child Neurol, November 1, 2003; 18(11): 772 - 775.
[Abstract] [PDF]

Home page
 J Clin PharmacolHome page
M. L. Christensen, R. K. Mottern, J. T. Jabbour, and E. Fuseau
Pharmacokinetics of Sumatriptan Nasal Spray in Adolescents
J. Clin. Pharmacol., July 1, 2003; 43(7): 721 - 726.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. W. Powers, S. R. Patton, K. A. Hommel, and A. D. Hershey
Quality of Life in Childhood Migraines: Clinical Impact and Comparison to Other Chronic Illnesses
Pediatrics, July 1, 2003; 112(1): e1 - 5.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. B. Berde and N. F. Sethna
Analgesics for the Treatment of Pain in Children
N. Engl. J. Med., October 3, 2002; 347(14): 1094 - 1103.
[Full Text] [PDF]

Home page
 PediatricsHome page
D. L. Fenster; and P. Winner
Migraine Treatment
Pediatrics, September 1, 2001; 108(3): 817 - 817.
[Abstract] [Full Text] [PDF]

Home page
 JWatch Emergency Med.Home page
Sumatriptan Nasal Spray for Adolescents with Migraines
Journal Watch Emergency Medicine, January 31, 2001; 2001(131): 5 - 5.
[Full Text]

Home page
 JWatch GeneralHome page
Sumatriptan for Adolescent Migraine
Journal Watch (General), November 10, 2000; 2000(1110): 5 - 5.
[Full Text]